American Well (NYSE:AMWL) Price Target Lowered to $5.00 at Stifel Nicolaus

American Well (NYSE:AMWL) had its target price cut by equities researchers at Stifel Nicolaus from $6.00 to $5.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has a “hold” rating on the stock. Stifel Nicolaus’ price objective suggests a potential downside of 12.05% from the stock’s current price.

Several other research firms have also recently issued reports on AMWL. Morgan Stanley decreased their price target on American Well from $10.50 to $6.00 and set an “equal weight” rating for the company in a research note on Thursday, December 18th. Wells Fargo & Company decreased their target price on shares of American Well from $12.00 to $9.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. Wall Street Zen downgraded shares of American Well from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of American Well in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $7.42.

American Well Trading Up 31.3%

American Well stock traded up $1.36 during midday trading on Friday, reaching $5.69. 356,103 shares of the stock traded hands, compared to its average volume of 105,126. American Well has a fifty-two week low of $3.71 and a fifty-two week high of $12.95. The firm has a market cap of $93.06 million, a price-to-earnings ratio of -0.80 and a beta of 1.36. The firm has a fifty day moving average price of $4.65 and a two-hundred day moving average price of $5.49.

American Well (NYSE:AMWL) last released its quarterly earnings results on Thursday, February 12th. The company reported ($1.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.59) by $0.07. The company had revenue of $55.31 million for the quarter, compared to analysts’ expectations of $52.71 million. American Well had a negative return on equity of 39.80% and a negative net margin of 42.80%. Analysts anticipate that American Well will post -9.34 earnings per share for the current year.

Insider Activity

In related news, insider Dmitry Zamansky sold 6,243 shares of the business’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $4.85, for a total value of $30,278.55. Following the sale, the insider directly owned 191,468 shares in the company, valued at $928,619.80. The trade was a 3.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last 90 days, insiders have sold 14,633 shares of company stock valued at $67,972. Insiders own 11.82% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Headlands Technologies LLC acquired a new stake in shares of American Well in the second quarter worth $39,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in American Well in the 3rd quarter worth about $62,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in American Well during the 2nd quarter worth about $89,000. Engineers Gate Manager LP purchased a new position in American Well during the 2nd quarter valued at about $101,000. Finally, Prelude Capital Management LLC acquired a new position in shares of American Well in the 3rd quarter valued at about $86,000. Institutional investors and hedge funds own 56.05% of the company’s stock.

Key Stories Impacting American Well

Here are the key news stories impacting American Well this week:

• Positive Sentiment: Q4 beat on EPS and revenue — Amwell reported ($1.52) EPS vs. consensus ($1.59) and revenue of $55.31M vs. $52.71M, showing higher top‑line and a narrower miss on profitability than expected. Conference call and press release provide the details investors cheered. Amwell Press Release
• Positive Sentiment: Analyst/coverage pieces emphasize earnings potential and strategic initiatives — Coverage (Benzinga) highlighted upside in Amwell’s earnings trajectory and longer‑term SaaS leverage that likely supported the rally. A Glimpse of American Well’s Earnings Potential
• Neutral Sentiment: Full earnings transcript is available — management discussed results, cost dynamics and contract activity; useful for parsing whether beats reflect sustainable trends or one‑time items. Read the transcript for color on bookings and margin cadence. Q4 2025 Earnings Transcript
• Neutral Sentiment: Call highlights show both progress and challenges — Yahoo’s call summary notes management navigating headwinds while securing some deals; useful to weigh substance behind the beat. Earnings Call Highlights
• Neutral Sentiment: Third‑party metric comparison — Zacks compares key metrics vs. estimates and year‑ago results, helping investors isolate drivers (revenue mix, bookings, cost trends). Zacks Analysis
• Negative Sentiment: Q1 2026 revenue guidance well below Street — management guided Q1 revenue to $48.0M–$53.0M versus consensus ~$59.9M, increasing risk of near‑term disappointment and expectations reset. (Guidance update released 2/12/2026)
• Negative Sentiment: FY2026 revenue guide also cut below consensus — FY revenue guidance $195M–$205M vs. consensus ~$243.5M, signaling a longer timeline to reach previous targets and pressuring valuation near term. (Guidance update released 2/12/2026)

American Well Company Profile

American Well, operating under the trade name Amwell, is a Boston-based digital health company that develops and delivers telehealth solutions to healthcare providers, payers, employers and patients. Through its cloud-based platform, the company enables secure virtual visits, remote patient monitoring and integrated care coordination across a range of medical disciplines, including primary care, behavioral health, chronic disease management and urgent care.

The company’s core offering, the Amwell Telehealth Platform, facilitates live video consultations, asynchronous messaging, e-prescribing and electronic health record integration.